The following article excerpt promotes various forms of autograft use in orthopedic oncology and while it describes historical high rates of complications for cancellous autograft harvesting (18% for iliac crest), I think the author might be someone we can approach to try the Corex device.
Autograft and Biologic Living Bone Reconstructions in Orthopaedic Oncology,” Matthew T. Wallace, MD, et al, American Academy of Orthopaedic Surgeons, 2026 Feb. 01; 34:e348-e357 “Cancellous autograft contains the full spectrum of marrow and bone remodeling cell populations; however, most transplanted cells in this graft die from ischemia and induced apoptosis. However, cancellous autograft has shown greater efficacy in healing compared with allograft, likely due to preservation of the primitive mesenchymal and endothelial progenitor cell populations that are more resistant to ischemia and proliferate in low O2 tension and low pH environments at the site of surgery. Graft resorption and new bone formation can be observed in a few weeks and remodeling by 6 months.”
